PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

King’s Doctoral Training Centre to investigate MS symptom management

Impacting more than 150,000 people in the UK, the lifelong autoimmune disease affects the brain and spinal cord.

A new King’s Doctoral Training Centre at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King’s College London (KCL) has been launched to investigate symptom management for multiple sclerosis (MS) without using drugs.

Funded by the MS Society, the new training centre will help treat symptoms including pain, sexual difficulties and psychological distress for MS patients who find it challenging to access non-drug treatments.

Affecting more than 150,000 people in the UK, MS is a lifelong autoimmune disease that affects the brain and spinal cord. It can lead to a wide range of potential symptoms, including problems with vision, arm or leg movement, sensation or balance.

Currently, drug treatments are available to help individuals living with the condition prevent relapses and slow down progression. However, for some, these drugs can have side effects and do not work for everyone.

The new training centre has recruited three PhD students to develop and test digital health interventions for MS, which will sit on a single digital platform called My MS Digital Symptom Toolkit.

The platform will enable people living with the condition to gain access to support for different symptoms in the same place, while making it easier for healthcare professionals to refer people to non-drug treatments.

The centre, which is also being supported by a digital health solution company, Avegen, aims to work with a patient and public involvement (PPI) group comprising people living with MS to oversee and add input into the work of the centre.

Rona Moss-Morris, co-lead of the Doctoral Training Centre and professor, psychology as applied to medicine, KCL’s IoPPN, commented: “We’re incredibly excited to be working in partnership with Avegen, the MS Society and people with MS on this project.

“Creating evidence-based digital interventions to enhance integrated care for people with challenging long-term conditions like MS is core to our mission.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026